Therapeutical strategies for recurrent endometrial cancer

Česká verze

Authors: Tomáš Crha ; Luboš Minář ; Michal Felsinger ; Vít Weinberger
Authors place of work: Onkogynekologické centrum, Gynekologicko-porodnická klinika LF MU a FN Brno
Published in the journal: Ceska Gynekol 2023; 88(4): 302-307
Category: Přehledová práce
doi: https://doi.org/10.48095/cccg2023302

Summary

Objective: A comprehensive overview of therapeutical strategies for recurrent endometrial cancer with illustrative case report. Methodology: A review providing basic overview of therapeutical options for different forms of recurrent endometrial cancer including surgical treatment, systemic treatment and radiotherapy. It includes a case report presenting a treatment of patient with an endometrial cancer recurrence in the abdominal wall. Conclusion: Therapeutical strategies in patients with endometrial cancer recurrence include surgical treatment, radiotherapy and systemic treatment depending on previous therapy, type and site of recurrence or dissemination, performance status and wishes of the patient. Decision about choice of treatment should be individually discussed and evaluated by multidisciplinary oncogynecological commission board.

Keywords:

surgery – endometrial cancer – radiotherapy – local recurrence – systemic treatment – distant recurrence

Zdroje

1. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita. 2007 [online]. Dostupné z: http: //www.svod.cz.

2. Legge F, Restaino S, Leone L et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment. Int J Gynecol Cancer 2020; 30 (2): 193–200. doi: 10.1136/ijgc- 2019-000822.

3. UK CR, Uterine cancer statistics. 2023 [online]. Available from: https: //www.cancerresear chuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine- cancer.

4. Xu Y, Burmeister C, Hanna RK et al. Predictors of survival after recurrence in women with early-stage endometrial carcinoma. Int J Gynecol Cancer 2016; 26 (6): 1137–1142. doi: 10.1097/IGC. 0000000000000733.

5. Concin N, Matias-Guiu X, Vergote I et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31 (1): 12–39. doi: 10.1136/ijgc-2020-002230.

6. Connor EV, Rose PG. Management strategies for recurrent endometrial cancer. Expert Rev Anticancer Ther 2018; 18 (9): 873–885. doi: 10.1080/14737140.2018.1491311.

7. Huh WK, Straughn JM Jr, Mariani A et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer 2007; 17 (4): 886–889. doi: 10.1111/ j.1525-14 38.2007.00858.x.

8. Creutzberg CL, van Putten WL, Koper PC et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003; 89 (2): 201–209. doi: 10.1016/s0090-8258 (03) 00126-4.

9. Llewelyn M, Taylor A. Re-irradiation of cervical and endometrial cancer. Curr Opin Oncol 2017; 29 (5): 343–350. doi: 10.1097/CCO.0000 000000000392.

10. Jereczek-Fossa B, Badzio A. Recurrent JJ. Endometrial cancer after surgery alone: results of salvage radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48 (2): 405–413. doi: 10.1016/s03 60-3016 (00) 00642-8.

11. Schmidt AM, Imesch P, Fink D et al. Pelvic exenterations for advanced and recurrent endometrial cancer: clinical outcomes of 40 patients. Int J Gynecol Cancer 2016; 26 (4): 716–721. doi: 10.1097/IGC.0000000000000678.

12. Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 2010; 118 (1): 14–18. doi: 10.1016/j.ygyno.2010.04. 005.

13. Minář L, Petrovová D, Kümmel J. Karcinom děložního těla – raritní varianta vzdálené metastázy. Ceska Gynekol 2009; 74 (5): 383–389.

14. Thigpen JT, Blessing JA, DiSaia PJ et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12 (7): 1408–1414. doi: 10.1200/JCO.1994.12.7. 1408.

15. van Wijk FH, Aapro MS, Bolis G et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003; 14 (3): 441–448. doi: 10.1093/annonc/mdg 112.

16. Miller DF, Filiaci V, Fleming G et al. Randomized phase III non inferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study. SGO abstract Late-Breaking Abstract 1. Gynecol Oncol 2012; 125 (Suppl): 771–773. doi: 10.1016/j.ygyno.2012.03.034.

17. Rubinstein M, Halpenny D, Makker V et al. Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: a retrospective study of the Memorial Sloan Kettering Cancer Center experience. Gynecol Oncol Rep 2019; 28: 120–123. doi: 10.1016/j.gore.2019.04. 002.

18. van Weelden WJ, Massuger LF, ENITEC et al. Anti-estrogen treatment in endometrial cancer: a systematic review. Front Oncol 2019; 9: 359. doi: 10.3389/fonc.2019.00359.

19. Ethier JL, Desautels DN, Amir E et al. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol 2017; 147 (1): 158–166. doi: 10.1016/j.ygyno.2017.07.002.

20. Mileshkin L, Edmondson R, O‘Connell RL et al. Phase 2 study of anastrozole in recurrent estrogen (ER) /progesterone (PR) positive endometrial cancer: the PARAGON trial – ANZGOG 0903. Gynecol Oncol 2019; 154 (1): 29–37. doi: 10.1016/j.ygyno.2019.05.007.

21. Marabelle A, Le DT, Ascierto PA et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38 (1): 1–10. doi: 10.1200/JCO.19.02105.

22. Mittica G, Ghisoni E, Giannone G et al. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget 2017; 8 (52): 90532–90544. doi: 10.18632/oncotarget.20042.

23. Makker V, Taylor MH, Aghajanian C et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020; 38 (26): 2981–2992. doi: 10.1200/JCO.19.02627.

24. Makker V, Rasco D, Vogelzang NJ et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019; 20 (5): 711–718. doi: 10.1016/S1470-2045 (19) 30020-8.

25. Fader AN, Roque DM, Siegel E et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 2018; 36 (20): 2044–2051. doi: 10.1200/JCO.2017.76.5966.